Plain-English translation of NCT07188090 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is studying whether a more selective use of during stem cell collection can help reduce a side effect called engraftment syndrome in patients undergoing autologous stem cell transplantation for blood cancers. Engraftment syndrome causes fever, rash, and fluid leakage after transplant. The study will compare outcomes in patients who need the medication versus those who don't, to see if using it only when necessary leads to better results.
Engraftment syndrome affects more than half of patients receiving stem cell transplants and can cause serious complications. Researchers want to know if using this medication more selectively—only when stem cell collection isn't going well—can reduce engraftment syndrome rates and improve patient outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive a growth factor medication (G-CSF) starting four days before your stem cell collection. On the collection day, doctors will use a special machine to collect blood stem cells from your bloodstream. If enough cells aren't collected on the first or second day, you'll receive the study medication () and continue collection until the goal is reached. After collection, you'll proceed with your planned stem cell transplant and be monitored for engraftment and any side effects.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States